Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

A Randomized Crossover Trial of Bright Light Therapy in Irritable Bowel Syndrome

NCT: NCT06676488 · COMPLETED

NCT IDNCT06676488
StatusCOMPLETED
Start Date2025-06-11
Completion2026-03-31

Brief Summary

The purpose of this research study is to assess whether morning bright light therapy (BLT) using a wearable device called a Re-Timer could potentially improve Irritable Bowel Syndrome (IBS) symptoms and decrease intestinal permeability (leaky gut). Morning bright light therapy will be administrated through a safe-wearable glasses device called a Re-Timer. The Re-Timer glasses are lightweight and deliver blue-green light at 500nm, mimicking exposure to natural light.

Frequently Asked Questions

What is A Randomized Crossover Trial of Bright Light Therapy in Irritable Bowel Syndrome?

A Randomized Crossover Trial of Bright Light Therapy in Irritable Bowel Syndrome is a clinical trial registered under NCT06676488. Current status: COMPLETED.

What is the status of NCT06676488?

The current status of NCT06676488 (A Randomized Crossover Trial of Bright Light Therapy in Irritable Bowel Syndrome) is: COMPLETED.

When did A Randomized Crossover Trial of Bright Light Therapy in Irritable Bowel Syndrome start?

A Randomized Crossover Trial of Bright Light Therapy in Irritable Bowel Syndrome started on 2025-06-11.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.